• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对多态性疟疾疫苗的菌株特异性体液反应。

Strain-specific humoral response to a polymorphic malaria vaccine.

作者信息

Flück Christian, Smith Tom, Beck Hans-Peter, Irion Andrea, Betuela Inoni, Alpers Michael P, Anders Robin, Saul Allan, Genton Blaise, Felger Ingrid

机构信息

Swiss Tropical Institute, Socinstrasse 57, Basel.

出版信息

Infect Immun. 2004 Nov;72(11):6300-5. doi: 10.1128/IAI.72.11.6300-6305.2004.

DOI:10.1128/IAI.72.11.6300-6305.2004
PMID:15501757
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC523016/
Abstract

The 3D7 form of the merozoite surface protein 2 (MSP2) of Plasmodium falciparum was one of three subunits of the malaria vaccine Combination B that were tested in a phase I/IIb double-blind randomized placebo-controlled trial, which was undertaken with 120 Papua New Guinean children of 5 to 9 years of age. Because only one variant of the highly polymorphic MSP2 was used for vaccination, we examined whether the elicited response was directed against conserved or strain-specific epitopes. Postvaccination (week 12) titers of antibody against recombinantly expressed individual domains of MSP2 were measured by enzyme-linked immunosorbent assay and compared to baseline values. We found that vaccination with the 3D7 form of MSP2 induced a significant strain-specific humoral response directed against the repetitive and semiconserved family-specific part. The conserved N- and C-terminal domains were not immunogenic. Titers of antibody against the alternate FC27 family-specific domain showed a tendency to increase in vaccinated children, but there was no increase in antibodies against FC27-type 32-mer repeats. These results indicate that vaccination with one MSP2 variant mainly induced a strain-specific response, which can explain the selective effect of vaccination with combination B on the genotypes of breakthrough parasites. These findings support the inclusion of both family-specific domains (3D7 and FC27) in an improved vaccine formulation.

摘要

恶性疟原虫裂殖子表面蛋白2(MSP2)的3D7形式是疟疾疫苗组合B的三个亚基之一,该疫苗在一项I/IIb期双盲随机安慰剂对照试验中进行了测试,试验对象为120名5至9岁的巴布亚新几内亚儿童。由于高度多态性的MSP2仅使用了一个变体进行疫苗接种,我们研究了引发的反应是针对保守表位还是菌株特异性表位。通过酶联免疫吸附测定法测量接种疫苗后(第12周)针对重组表达的MSP2各个结构域的抗体滴度,并与基线值进行比较。我们发现,用MSP2的3D7形式进行疫苗接种可诱导针对重复且半保守的家族特异性部分的显著菌株特异性体液反应。保守的N端和C端结构域没有免疫原性。针对替代的FC27家族特异性结构域的抗体滴度在接种疫苗的儿童中显示出增加的趋势,但针对FC27型32聚体重复序列的抗体没有增加。这些结果表明,用一种MSP2变体进行疫苗接种主要诱导了菌株特异性反应,这可以解释组合B疫苗接种对突破性寄生虫基因型的选择性作用。这些发现支持在改进的疫苗配方中同时包含家族特异性结构域(3D7和FC27)。

相似文献

1
Strain-specific humoral response to a polymorphic malaria vaccine.针对多态性疟疾疫苗的菌株特异性体液反应。
Infect Immun. 2004 Nov;72(11):6300-5. doi: 10.1128/IAI.72.11.6300-6305.2004.
2
Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity.疟疾疫苗组合B对裂殖子表面抗原2多样性的影响。
Infect Genet Evol. 2007 Jan;7(1):44-51. doi: 10.1016/j.meegid.2006.03.006. Epub 2006 May 2.
3
Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.评估两种长合成裂殖子表面蛋白2肽作为疟疾疫苗候选物的情况。
Vaccine. 2009 May 5;27(20):2653-61. doi: 10.1016/j.vaccine.2009.02.081. Epub 2009 Mar 6.
4
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.在巴布亚新几内亚进行的一项1/2b期试验中,一种重组血液期疟疾疫苗可降低恶性疟原虫密度,并对寄生虫种群施加选择压力。
J Infect Dis. 2002 Mar 15;185(6):820-7. doi: 10.1086/339342. Epub 2002 Feb 14.
5
Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.一种重组疟疾候选疫苗(恶性疟原虫AMA-1胞外结构域的I+II结构域,来自印度恶性疟原虫等位基因)的免疫原性。
Vaccine. 2008 Aug 18;26(35):4526-35. doi: 10.1016/j.vaccine.2008.06.031. Epub 2008 Jun 30.
6
Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.由疟疾疫苗候选物裂殖子表面蛋白2嵌合体产生的应变超越免疫反应。
Sci Rep. 2016 Feb 11;6:20613. doi: 10.1038/srep20613.
7
Plasmodium falciparum: sequence diversity and antibody recognition of the Merozoite surface protein-2 (MSP-2) in Brazilian Amazonia.恶性疟原虫:巴西亚马逊地区裂殖子表面蛋白-2(MSP-2)的序列多样性与抗体识别
Exp Parasitol. 2004 Nov-Dec;108(3-4):114-25. doi: 10.1016/j.exppara.2004.08.001.
8
Variant-specific antibodies to merozoite surface protein 2 and clinical expression of Plasmodium falciparum malaria in rural Amazonians.针对裂殖子表面蛋白2的变异特异性抗体与亚马逊地区农村居民恶性疟原虫疟疾的临床表现
Am J Trop Med Hyg. 2007 Jun;76(6):1084-91.
9
Plasmodium falciparum: distribution of msp2 genotypes among symptomatic and asymptomatic individuals from the Wosera region of Papua New Guinea.恶性疟原虫:巴布亚新几内亚沃塞拉地区有症状和无症状个体中msp2基因型的分布情况
Exp Parasitol. 2004 Jan-Feb;106(1-2):22-9. doi: 10.1016/j.exppara.2004.01.010.
10
Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2.恶性疟原虫裂殖子表面蛋白2不同等位基因之间的抗原交叉反应性。
Parasite Immunol. 2003 Nov-Dec;25(11-12):531-43. doi: 10.1111/j.0141-9838.2004.00664.x.

引用本文的文献

1
Allelic frequency of 2 and genes in isolates from Awka, Anambra, Nigeria.尼日利亚阿南布拉州奥卡分离株中2和基因的等位基因频率。
Malariaworld J. 2025 Feb 18;16:4. doi: 10.5281/zenodo.14886922. eCollection 2025.
2
Naturally acquired IgG responses to do not target the conserved termini of the malaria vaccine candidate Merozoite Surface Protein 2.对疟疾疫苗候选物裂殖子表面蛋白2的天然获得性IgG反应并不针对其保守末端。
Front Immunol. 2024 Dec 9;15:1501700. doi: 10.3389/fimmu.2024.1501700. eCollection 2024.
3
T-follicular helper cells in malaria infection and roles in antibody induction.疟疾感染中的T滤泡辅助细胞及其在抗体诱导中的作用。
Oxf Open Immunol. 2021 Apr 10;2(1):iqab008. doi: 10.1093/oxfimm/iqab008. eCollection 2021.
4
In silico characterisation of putative Plasmodium falciparum vaccine candidates in African malaria populations.在非洲疟疾人群中对疑似疟原虫疫苗候选物的计算机分析。
Sci Rep. 2021 Aug 10;11(1):16215. doi: 10.1038/s41598-021-95442-4.
5
Host-Malaria Parasite Interactions and Impacts on Mutual Evolution.宿主-疟原虫相互作用及其对共同进化的影响。
Front Cell Infect Microbiol. 2020 Oct 27;10:587933. doi: 10.3389/fcimb.2020.587933. eCollection 2020.
6
Disordered epitopes as peptide vaccines.作为肽疫苗的无序表位
Pept Sci (Hoboken). 2018 May;110(3):e24067. doi: 10.1002/pep2.24067. Epub 2018 Apr 14.
7
High-resolution micro-epidemiology of parasite spatial and temporal dynamics in a high malaria transmission setting in Kenya.肯尼亚高疟疾传播环境中寄生虫时空动态的高分辨率微观流行病学。
Nat Commun. 2019 Dec 9;10(1):5615. doi: 10.1038/s41467-019-13578-4.
8
Reflections on pneumonia in the tropics.关于热带地区肺炎的思考。
Pneumonia (Nathan). 2014 Dec 1;4:1-7. doi: 10.15172/pneu.2014.4/416. eCollection 2014.
9
Immunogenicity analysis of genetically conserved segments in Plasmodium ovale merozoite surface protein-8.卵形疟原虫裂殖子表面蛋白 8 中遗传保守片段的免疫原性分析。
Parasit Vectors. 2019 Apr 11;12(1):164. doi: 10.1186/s13071-019-3412-0.
10
Regulating STING in health and disease.调控健康与疾病中的STING蛋白。
J Inflamm (Lond). 2017 Jun 7;14:11. doi: 10.1186/s12950-017-0159-2. eCollection 2017.

本文引用的文献

1
Antigenic cross-reactivity between different alleles of the Plasmodium falciparum merozoite surface protein 2.恶性疟原虫裂殖子表面蛋白2不同等位基因之间的抗原交叉反应性。
Parasite Immunol. 2003 Nov-Dec;25(11-12):531-43. doi: 10.1111/j.0141-9838.2004.00664.x.
2
Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.一种针对巴布亚新几内亚儿童恶性疟原虫的三组分血液期疟疾疫苗(MSP1、MSP2、RESA)的安全性和免疫原性。
Vaccine. 2003 Dec 8;22(1):30-41. doi: 10.1016/s0264-410x(03)00536-x.
3
Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria.血清中针对恶性疟原虫裂殖子表面蛋白2的IgG3与疟疾预期风险降低密切相关。
Parasite Immunol. 2003 Jun;25(6):307-12. doi: 10.1046/j.1365-3024.2003.00636.x.
4
Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2.恶性疟原虫的遗传多样性和抗原多态性:裂殖子表面蛋白2等位基因变体之间广泛的血清学交叉反应性。
Infect Immun. 2003 Jun;71(6):3485-95. doi: 10.1128/IAI.71.6.3485-3495.2003.
5
Molecular monitoring in malaria vaccine trials.疟疾疫苗试验中的分子监测
Trends Parasitol. 2003 Feb;19(2):60-3. doi: 10.1016/s1471-4922(02)00066-1.
6
Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali.在马里班迪亚拉一个疟疾疫苗测试地点,季前治疗对恶性疟发病率和寄生虫密度的影响。
Am J Trop Med Hyg. 2002 Dec;67(6):604-10. doi: 10.4269/ajtmh.2002.67.604.
7
Does radical cure of asymptomatic Plasmodium falciparum place adults in endemic areas at increased risk of recurrent symptomatic malaria?根治无症状恶性疟原虫会使流行地区的成年人面临复发性症状性疟疾风险增加吗?
Trop Med Int Health. 2002 Jul;7(7):599-603. doi: 10.1046/j.1365-3156.2002.00902.x.
8
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.在巴布亚新几内亚进行的一项1/2b期试验中,一种重组血液期疟疾疫苗可降低恶性疟原虫密度,并对寄生虫种群施加选择压力。
J Infect Dis. 2002 Mar 15;185(6):820-7. doi: 10.1086/339342. Epub 2002 Feb 14.
9
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.RTS,S/AS02疟疾疫苗对冈比亚半免疫成年男性恶性疟原虫感染的疗效:一项随机试验。
Lancet. 2001 Dec 8;358(9297):1927-34. doi: 10.1016/S0140-6736(01)06957-4.
10
Antibody responses to infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein 2.针对表达不同形式裂殖子表面蛋白2的恶性疟原虫菌株感染的抗体反应。
Infect Immun. 2001 Feb;69(2):959-67. doi: 10.1128/IAI.69.2.959-967.2001.